Joint Offering Empowers Biopharma with Unique Datasets for Discovery of Novel Oncology Research Insights
The reports provide a comprehensive overview of the digital pathology implementation experiences at the University of Michigan and Mayo Clinic, showcasing the benefits, challenges, and future potential of digital and AI technologies in pathology.
Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the U.S. Food and Drug Administration (FDA) has issued a 510(k) clearance to Indica Labs for HALO AP Dx, an enterprise digital pathology platform. HALO AP Dx is indicated for primary diagnosis of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue scanned by the NanoZoomer® S360MD Slide scanner¹. This 510(k) clearance from the FDA expands on an established partnership between Indica Labs and Hamamatsu Photonics K.K.
Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for cancer and kidney disease, and HistoWiz, a leading provider of histology and slide archiving services, today announced a pilot study to evaluate the benefits of integrating Aiosyn’s NephroPath kidney analysis algorithms onto HistoWiz’s PathologyMap™ digital pathology platform. This collaboration aims to advance kidney pathology analysis and research, by allowing PathologyMap users direct access to NephroPath algorithms without any additional software.
AISight IMS enables pathology labs to be at the forefront of emerging and state-of-the-art digital pathology technologies and workflows.
Deep Bio utilizes deep learning-based algorithms to differentiate breast cancer lesions accurately, optimizing diagnostic accuracy.
Bedfordshire Hospital NHSFT, working against the challenges of increased case complexity and COVID-19 impacts, sought Diagnexia’s off-site histopathology reporting services to improve turnaround times for diagnostic reports.
Pathology News is pleased to bring you a report on the Digital Pathology & AI Congress: USA, a landmark event highlighting the forefront of digital innovation in digital pathology. In this initial article, we introduce the meeting, offer an overview of the latest developments and insights, let you know what’s to come from this series and offer a preview of the report’s key highlights.
Throughout history, pathology has remained an integral component of medicine, tracing its origins to ancient healers recognizing the importance of understanding disease processes for effective treatments. What began as speculative observations has since evolved into a complex specialty characterized by precise assessments, predictive diagnosis, and advanced imaging modalities. This transformation has been driven by technological advances that have revolutionized this field time and time again.
Lumea, a trailblazing digital pathology company dedicated to advancing tissue standardization, is thrilled to announce a standalone version of their Smart Tissue Camera—the BxCam® that requires no LIS integration. Historically, this unique device was only available to those using Lumea’s complete software package known as BxLink™. Now, at an affordable price tag, this incredible technology is accessible to labs of all sizes.
